LONDON, June 12 (Reuters) - UCB’s drug Cimzia stops structural damage to joints in patients with rheumatoid arthritis as soon as 16 weeks after the start of treatment, according to new data presented on Thursday.
LONDON, June 12 (Reuters) - UCB’s drug Cimzia stops structural damage to joints in patients with rheumatoid arthritis as soon as 16 weeks after the start of treatment, according to new data presented on Thursday.
